Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.

@article{Quteineh2008InfluenceOC,
  title={Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.},
  author={Lina Quteineh and C{\'e}line Verstuyft and V{\'a}lerie Furlan and Antoine Durrbach and Alexia Letierce and Sophie Ferlicot and A -M. Taburet and Bernard Charpentier and Laurent Becquemont},
  journal={Basic & clinical pharmacology & toxicology},
  year={2008},
  volume={103 6},
  pages={546-52}
}
Tacrolimus is a widely used immunosuppressive drug in organ transplantation. Its oral bioavailability varies greatly between individuals, and it is a substrate of cytochrome P450 3A (CYP3A) and P-glycoprotein. Our objective was to determine the influence of CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus daily requirements and on transplantation outcome. One hundred and thirty-six renal graft recipients treated with tacrolimus were genotyped for CYP3A5 (6986A>G), ABCB1 exon26 (3435C>T) and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

Similar Papers

Loading similar papers…